Cross-source evidence timeline

Albiglutide research timeline

Follow 19 selected, directly cited source records from April 15, 2014 through February 1, 2021. This timeline joins source lanes for navigation; it does not infer that one record confirms another.

19Selected records
8Source years
3Evidence lanes
February 1, 2021Latest source date

Source year

2021

1 record
  1. Literature metadata

    Randomized 52-week Phase 2 Trial of Albiglutide Versus Placebo in Adult Patients With Newly Diagnosed Type 1 Diabetes.↗

    PubMed lists PMID 32219329 in The Journal of clinical endocrinology and metabolism as Clinical Trial, Phase II, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, and 1 more PubMed publication type, with publication-date metadata of 2020-06-01 (day precision). PeptideScanner associated the retained record with the identity slug albiglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2020

1 record
  1. Clinical trials

    ClinicalTrials.gov record NCT02229227↗

    PeptideScanner retained ClinicalTrials.gov record NCT02229227 at 2026-11-16T17:45:42.793Z. Its registry update date was 2020-11-27, and PeptideScanner's reviewed identity mapping was albiglutide.↗

Source year

2019

1 record
  1. Literature metadata

    Albiglutide for the treatment of type 2 diabetes mellitus.↗

    PubMed lists PMID 28085780 in The Nurse practitioner as Journal Article, with publication-date metadata of 2017-02-12 (day precision). PeptideScanner associated the retained record with the identity slug albiglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2018

1 record
  1. Literature metadata

    Albiglutide (Tanzeum) for Diabetes Mellitus.↗

    PubMed lists PMID 28409609 in American family physician as Journal Article, Review, with publication-date metadata of 2017-04-15 (day precision). PeptideScanner associated the retained record with the identity slug albiglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2017

12 records
  1. Clinical trials

    ClinicalTrials.gov record NCT00938158↗

    PeptideScanner retained ClinicalTrials.gov record NCT00938158 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-07-21, and PeptideScanner's reviewed identity mapping was albiglutide.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT01077505↗

    PeptideScanner retained ClinicalTrials.gov record NCT01077505 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-06-14, and PeptideScanner's reviewed identity mapping was albiglutide.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT01406262↗

    PeptideScanner retained ClinicalTrials.gov record NCT01406262 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-06-08, and PeptideScanner's reviewed identity mapping was albiglutide.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT01777282↗

    PeptideScanner retained ClinicalTrials.gov record NCT01777282 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-05-03, and PeptideScanner's reviewed identity mapping was albiglutide.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT01098539↗

    PeptideScanner retained ClinicalTrials.gov record NCT01098539 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-02-28, and PeptideScanner's reviewed identity mapping was albiglutide.↗

  6. Clinical trials

    ClinicalTrials.gov record NCT01098461↗

    PeptideScanner retained ClinicalTrials.gov record NCT01098461 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-01-13, and PeptideScanner's reviewed identity mapping was albiglutide.↗

  7. Clinical trials

    ClinicalTrials.gov record NCT01475734↗

    PeptideScanner retained ClinicalTrials.gov record NCT01475734 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-01-11, and PeptideScanner's reviewed identity mapping was albiglutide.↗

  8. Clinical trials

    ClinicalTrials.gov record NCT00838903↗

    PeptideScanner retained ClinicalTrials.gov record NCT00838903 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-01-09, and PeptideScanner's reviewed identity mapping was albiglutide.↗

  9. Clinical trials

    ClinicalTrials.gov record NCT00838916↗

    PeptideScanner retained ClinicalTrials.gov record NCT00838916 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-01-09, and PeptideScanner's reviewed identity mapping was albiglutide.↗

  10. Clinical trials

    ClinicalTrials.gov record NCT00839527↗

    PeptideScanner retained ClinicalTrials.gov record NCT00839527 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-01-09, and PeptideScanner's reviewed identity mapping was albiglutide.↗

  11. Clinical trials

    ClinicalTrials.gov record NCT00849017↗

    PeptideScanner retained ClinicalTrials.gov record NCT00849017 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-01-09, and PeptideScanner's reviewed identity mapping was albiglutide.↗

  12. Clinical trials

    ClinicalTrials.gov record NCT00849056↗

    PeptideScanner retained ClinicalTrials.gov record NCT00849056 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-01-09, and PeptideScanner's reviewed identity mapping was albiglutide.↗

Source year

2016

1 record
  1. Regulatory

    Federal Register notice 2016-13797↗

    The Federal Register published notice 2016-13797, attributed to FDA and its parent HHS department, on 2016-06-10. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; TANZEUM,” and PeptideScanner's exact reviewed identity mapping connects the document to Albiglutide.↗

Source year

2015

1 record
  1. Literature metadata

    Apremilast, albiglutide, and empagliflozin.↗

    PubMed lists PMID 25216888 in Journal of the American Pharmacists Association : JAPhA as Journal Article, with publication-date metadata of 2014 Sep-Oct (source-text precision). PeptideScanner associated the retained record with the identity slug albiglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2014

1 record
  1. Regulatory

    Drugs@FDA application BLA125431↗

    The official Drugs@FDA dataset lists original submission 1 for BLA 125431 with status AP dated 2014-04-15, and names albiglutide among the application record's active ingredients.↗